🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  2. TETRACOSACTIDE , BETAMETHASONE , Placebo of fludrocortisone, Placebo of hydrocortisone hemisuccinate, FLUDROCORTISONE , HYDROCORTISONE HEMISUCCINATE

    Pari Pharma GmbH

    Critically ill patients suffering from CIRCI

    phase 3 small molecule active

    1 trial

  3. TEV-45779

    Teva Pharma GmbH

    Chronic Urticaria

    phase 3 other completed

    1 trial

  4. TEV-50717

    Teva Pharma GmbH

    Cerebral Palsy, Dyskinetic

    phase 3 small molecule terminated

    2 trials

  5. TEV-50717

    Teva Pharma GmbH

    Tourette Syndrome

    phase 3 small molecule terminated

    3 trials

  6. TEV-56248

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule active

    2 trials

  7. TEZ

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  8. TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  9. TMC125

    Elan Pharma International

    HIV-1

    phase 3 small molecule completed

    1 trial

  10. TNX-102 SL

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule terminated

    6 trials

  11. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  12. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  13. TNX-102 SL 2.8mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  14. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule completed

    1 trial

  15. TNX-102 SL Tablet 2.8 mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  16. TNX-102 SL Tablet, 2.8 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  17. TNX-102 SL Tablet, 2.8mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  18. TNX-102 SL Tablet, 5.6 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  19. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial

  20. TOPOTECAN, TOPOTECAN, IRINOTECAN, TOPOTECAN, lurbinectedin, TOPOTECAN

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  21. TP-03

    Tarsus Pharmaceuticals

    Blepharitis

    phase 3 small molecule completed

    1 trial

  22. TP-03, 0.25%

    Tarsus Pharmaceuticals

    Blepharitis

    phase 3 small molecule completed

    1 trial

  23. TQJ230

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  24. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources